Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Relapsed Ovarian, Endometrial, and Cervical Cancers
NCT06865677Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2025
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in ovarian cancer, endometrial cancer (EC), Cervical Cancer (CC), sponsored by National Cancer Institute. Started Jun 2025; status: terminated.
02
Drugs
sacituzumab govitecan
03
Conditions
ovarian cancerendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06865677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06865677.